Why did Quest raise its 2024 revenue guidance while keeping adjusted EPS guidance roughly unchanged?

The revenue increase reflects contributions from recent acquisitions, including LifeLabs. Adjusted EPS guidance was narrowed to $8.85–$8.95 from $8.80–$9.00, keeping the midpoint at $8.90. Management indicated that acquisition revenue offset the expected Hurricane Milton impact of about $0.08 per share in Q4.

How much of Quest's growth is organic versus acquisition-driven?

Third-quarter revenue grew 8.5%, of which 4.2% was organic, meaning roughly half of the growth came from acquisitions. Organic requisition volume grew only 0.5%, while total requisition volume grew 5.5%, indicating acquisitions drove most of the volume increase.

Why did operating margins decline despite revenue growth?

Reported operating margin fell to 13.3% from 14.9%, and adjusted margin fell to 15.5% from 16.6%. Selling, general and administrative expenses rose to $448 million from $380 million, and amortization of intangibles increased to $32 million from $27 million, largely reflecting recent acquisitions. Cost of services as a percentage of revenue also rose, from 67.2% to 67.4%.

How is Quest funding its acquisitions, and what does the balance sheet look like?

Quest spent about $1.78 billion on business acquisitions in the first nine months of 2024, funded largely by new borrowings of $1.85 billion. Total long-term debt (including the current portion) rose to about $6.25 billion from about $4.71 billion at year-end 2023. Cash rose modestly to $764 million, and the company continued paying dividends of $247 million for the nine months.

What are the key risks or items to monitor from this report?

Investors should watch organic volume growth, which was only 0.5% in the quarter; margin compression from acquisition integration and amortization; the impact of Hurricane Milton in Q4; and rising leverage. Management expects accelerated revenue and earnings growth in 2025 as acquisitions contribute, so execution on the planned eight acquisitions by year-end will be important.

DGX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 22, 2024. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) reported third quarter 2024 results on October 22, 2024, with revenues of $2.49 billion^a, up 8.5% year over year, including 4.2% organic growth.

Reported diluted EPS rose 1.5% to $1.99^b, while adjusted diluted EPS rose 3.6% to $2.30. Growth was driven by new customer wins, expanded business with physicians and hospitals, and recent acquisitions, most notably LifeLabs. Operating margin on a reported basis declined to 13.3% from 14.9%, while adjusted operating margin fell to 15.5% from 16.6%, reflecting acquisition-related dilution and higher amortization and integration costs.

Cash from operations improved 72.5% to $356 million^c in the quarter and 17.0% to $870 million for the nine months. management raised full-year 2024 revenue guidance to $9.80–$9.85 billion (5.9%–6.5% growth) from $9.50–$9.58 billion, reflecting acquisition contributions. Reported diluted EPS guidance was narrowed to $7.60–$7.70 from $7.57–$7.77, and adjusted diluted EPS guidance was narrowed to $8.85–$8.95 from $8.80–$9.00, with the adjusted midpoint maintained at $8.90. Hurricane Milton is expected to reduce fourth-quarter revenue by about $15 million and EPS by about $0.08.

Cash from operations and capital expenditure guidance were unchanged at roughly $1.3 billion^d and $420 million, respectively. For investors, the quarter shows solid top-line momentum driven by acquisitions and volume gains, with organic requisition volume growing only 0.5%, a key metric to monitor.

Leverage has risen, with long-term debt increasing to $5.6 billion from $4.4 billion at year-end 2023 following about $1.8 billion in acquisition spending in the first nine months. Management expects accelerated revenue and earnings growth in 2025 as acquisitions contribute.

02—Key points

Key Highlights

Q3 2024 revenue of $2.49 billion, up 8.5% year over year, with 4.2% organic growth
Q3 reported diluted EPS of $1.99 (up 1.5%); adjusted diluted EPS of $2.30 (up 3.6%)
Full-year 2024 revenue guidance raised to $9.80–$9.85 billion from $9.50–$9.58 billion, driven by acquisitions including LifeLabs
Adjusted diluted EPS guidance narrowed to $8.85–$8.95 (midpoint of $8.90 unchanged); reported EPS guidance narrowed to $7.60–$7.70
Hurricane Milton expected to reduce Q4 revenue by about $15 million and EPS by about $0.08
Q3 operating margin declined to 13.3% (reported) and 15.5% (adjusted) from 14.9% and 16.6%, reflecting amortization and integration costs
Long-term debt rose to $5.65 billion from $4.41 billion at year-end 2023 to fund about $1.78 billion of nine-month acquisition spending; organic requisition volume grew only 0.5%

03—Questions

Frequently Asked Questions

Why did Quest raise its 2024 revenue guidance while keeping adjusted EPS guidance roughly unchanged?
The revenue increase reflects contributions from recent acquisitions, including LifeLabs. Adjusted EPS guidance was narrowed to $8.85–$8.95 from $8.80–$9.00, keeping the midpoint at $8.90. Management indicated that acquisition revenue offset the expected Hurricane Milton impact of about $0.08 per share in Q4.
How much of Quest's growth is organic versus acquisition-driven?
Third-quarter revenue grew 8.5%, of which 4.2% was organic, meaning roughly half of the growth came from acquisitions. Organic requisition volume grew only 0.5%, while total requisition volume grew 5.5%, indicating acquisitions drove most of the volume increase.
Why did operating margins decline despite revenue growth?
Reported operating margin fell to 13.3% from 14.9%, and adjusted margin fell to 15.5% from 16.6%. Selling, general and administrative expenses rose to $448 million from $380 million, and amortization of intangibles increased to $32 million from $27 million, largely reflecting recent acquisitions. Cost of services as a percentage of revenue also rose, from 67.2% to 67.4%.
How is Quest funding its acquisitions, and what does the balance sheet look like?
Quest spent about $1.78 billion on business acquisitions in the first nine months of 2024, funded largely by new borrowings of $1.85 billion. Total long-term debt (including the current portion) rose to about $6.25 billion from about $4.71 billion at year-end 2023. Cash rose modestly to $764 million, and the company continued paying dividends of $247 million for the nine months.
What are the key risks or items to monitor from this report?
Investors should watch organic volume growth, which was only 0.5% in the quarter; margin compression from acquisition integration and amortization; the impact of Hurricane Milton in Q4; and rising leverage. Management expects accelerated revenue and earnings growth in 2025 as acquisitions contribute, so execution on the planned eight acquisitions by year-end will be important.

04—Continue

← View all 8-K filings